TNF-α-IN-28 (compound 4ea) is a TNF-α and NF-κB inhibitor with anti-inflammatory activity. TNF-α-IN-28 inhibits TNF-α and NF-κB expression. TNF-α-IN-28 interacts with TNF-α dimer.

TMEM175 modulator 3 (Compound 14) is a TMEM175 modulator. TMEM175 modulator 3 can be used in research on neurodegenerative diseases.

TLX agonist 3 is a potent and selective tailless homolog (TLX, NR2E1) agonist with an EC50 of 0.25 μM and a Kd of 1.6 μM). TLX agonist 3 shows high selectivity over related nuclear receptors, and promotes TLX oligomerization with an EC50 of 5.0 μM. TLX agonist 3 can be used for the research of neurodegenerative diseases.

TLR9 antagonist 2 is a highly selective and water-soluble TLR9 antagonist with an IC50 of 13 nM against human TLR9. TLR9 antagonist 2 inhibits CpG-induced production of the pro-inflammatory cytokine IL-6. TLR9 antagonist 2 is applicable for research on systemic, TLR9-mediated uncontrolled inflammatory responses, such as sepsis.

TLR7 antagonist-1 (Compound 44#) is an orally active, selective TLR7 antagonist with an IC50 value of 0.3 nM against TLR7. TLR7 antagonist-1 selectively binds to TLR7, inhibits its activation, and downregulates the c-Rel signaling pathway. TLR7 antagonist-1 downregulates the mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α. TLR7 antagonist-1 alleviates Imiquimod-induced psoriasis-like skin lesions. TLR7 antagonist-1 is applicable to research related to psoriasis.

TLR7 agonist 33 (Compound 141) is a potent TLR7 activator with an EC50 of 1 nM. TLR7 agonist 33 can be used for cancer research.

TKL002 is a blood-brain barrier-permeable inhibitor of the CTH/H2S/NF-κB/EMT signaling axis. TKL002 induces G2/M phase cell cycle arrest and apoptosis in glioblastoma cells. TKL002 inhibits the migration and invasion of glioblastoma cells by upregulating E-cadherin and downregulating N-cadherin and vimentin. TKL002 is applicable to relevant research on glioblastoma.

Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce triglycerides and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.

THR-β modulator-3 (Compound 75-2) is a THR-β modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity.

Thalidomide-5-F-6-piperidinylpiperazin is an ligands for E3 ligase-linker conjugate, which is used for the synthesis of PROTAC CDK9 degrader-9.

tert-Butyl 4-(methylamino)butylcarbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(3-hydroxypropyl)tetrahydropyridine-1(2H)-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 3-cyanoazetidine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

Terbequinil (SR-25776) is a potent orally active Gamma-aminobutyric acid A (GABAA) receptor inverse agonist. Terbequinil can be used for research on nervous system diseases.

Terazosin-md (compound TZ-md), a derivative of both Alfuzosin and Terazosin, is an orally active α1-adrenergic receptor antagonist. Terazosin-md has the functions of improving mitochondrial metabolism, degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin-md shows effect in a mouse model with Alzheimer's disease. Terazosin-md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders.

TCO-amine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. TCO-amine hydrochloride is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

TCCNeu5Ac (compound H-56) is a high-affinity and selective trisaccharide glycan ligand for Siglec-1 (CD169). TCCNeu5Ac azide can be conjugated to lipids to selectively target cells expressing either murine or human CD169 in vitro, exhibiting in vivo targeting to CD169-positive macrophages. TCCNeu5Ac can be used for in vivo macrophage delivery.

Talampicillin (hydrochloride) is a ampicillin derivative. Talampicillin (hydrochloride) is a thiazolide carboxylic ester of ampicillin. Talampicillin (hydrochloride) can be studied in research on urinary infection.

TACE-IN-1 is an orally active hydantoin-based tumor necrosis factor-α converting enzyme (TACE) inhibitor. TACE-IN-1 inhibits the production of TNF-α in human whole blood. TACE-IN-1 can be prepared as a stable neutral form. TACE-IN-1 can be used in anti-inflammatory research.

SYAF080 is a human A₂B adenosine receptor (hA₂B AdoR) antagonist with a Ki of 23.6 nM and a KB of 25.2 nM. SYAF080no relevant inhibition of human CYP450 cytochromes. SYAF080 can be used for the research of inflammation, metabolic and cardiovascular disease.

Sumacetamol (SUR 2647) is the N-acetyl-DL-methionine ester of Paracetamol. Sumacetamol is orally active. Sumacetamol enhances the hepatic GSH synthesizing capacity in Bom:NMRI mice after experimental overdosage and offers protection of hepatic cell integrity, when combined with Paracetamol .

SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. SU212 can selectively induce oxidative phosphorylation, reduce glycolysis activity and glucose uptake in tumor cells, and directly bind to ENO1 without affecting these pathways in normal cells. SU212 induces apoptosis and promotes ENO1 degradation via proteasomal and autophagic pathways without inhibiting the catalytic activity. SU212 leads to mitotic arrest and apoptosis in TNBC (triple-negative breast cancer) cells by activating AMPK, demonstrating potent anti-tumor activity in vitro. SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, exhibiting an excellent safety profile. SU212 can be used in research on t TNBC, diabetes, and fatty liver disease.

Steroid sulfatase-IN-11 is a steroid sulfatase inhibitor, which functionally inhibits steroid sulfatase activity, reducing the enzyme's ability to hydrolyze steroid sulfates. Steroid sulfatase-IN-11 can be used for the research of hormone-dependent cancers.

STAT6-IN-11 (example 3) is a STAT6 inhibitor with an EC50 of 6 nM. STAT6-IN-11 inhibits CCL17 secretion in peripheral human whole blood, stimulated through the IL-13-IL- 13 receptor/IL-4 receptor pathway, with an IC50 of 83 nM. STAT6-IN-11 can be used for the study of dermatological condition or a respiratory condition.

STAT3-IN-33 (compound 7f) is a potent STAT3 inhibitor with anti-cancer activity. STAT3-IN-33 exhibits antiproliferative activity in HCT116, MCF-7, and MDA-MB-231 cells, with IC50s of 6.44, 3.29, and 4.86 μM, respectively. STAT3-IN-33 can be used for breast and colon cancer research.

WAY-230563 (ST045945) is a serine/threonine kinase inhibitor that can block CHK1/CHK2-mediated cell cycle checkpoints. WAY-230563 can induce G2/M phase arrest and DNA damage in tumor cells.

SR-THAP is a γ-aminobutyric acid transporter 3 (GAT3) inhibitor with an IC50 of 4.9 μM, and exhibits 42-fold and 23-fold selectivity over GAT1 and GlyT1, respectively. SR-THAP inhibits GABA uptake in mammalian cells. SR-THAP is applicable to the research of epilepsy, Alzheimer's disease and ischemic stroke.

SR-5037 is an orally active CDK12 (IC50 = 31 nM)/CDK13 inhibitor and CycK (DC50 = 30 nM;Dmax > 98%) molecular glue degrader. SR-5037 inhibits the enzymatic activity of CDK12/CycK and CDK13/CycK complexes. SR-5037 promotes the recruitment of DDB1 to the CDK12/CycK complex, thereby triggering proteasome-mediated CycK degradation. SR-5037 degrades active CycK in mouse models of triple-negative breast cancer. SR-5037 can be used in the research of cancers such as triple-negative breast cancer.

SOS1-IN-25 is an SOS1 inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRASG12C/SOS1 complex formation (IC50 = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia.

SNA A(Bz) amidite is a phosphoramide monomer that can be used to synthesize oligonucleotides.